Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

Contact:Joshua T. Brumm
Executive Vice President, Finance
Phone: 408-215-3311

Ramses Erdtmann
Vice President of Investor Relations
Phone: 408-215-3325Pharmacyclics, Inc.
Condensed Consolidated Balance Sheets
(unaudited; in thousands)

 December 31,June 30, 20122012AssetsCash, cash equivalents and marketable securities 1

$
317,114$
203,607Other current assets 2

29,3789,788Total current assets

346,492213,395Property and equipment, net

6,4033,842Other assets

2,2341,883Total assets

$
355,129$
219,120Liabilities and Stockholders' EquityDeferred revenue - current portion

$
8,139$
8,054Other current liabilities

21,11810,932Total current liabilities

29,25718,986Deferred revenue - non-current portion

62,56267,324Deferred rent

784687Total liabilities

92,60386,997Stockholders' equity

262,526132,123Total liabilities and stockholders' equity

$
355,129$
219,1201Marketable securities

$
9,681$
5,7112As of December 31, 2012 and June 30, 2012, Other current assets includes $26.6 million and $5.8 million, respectively, due to t
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today announced ... Molecular Intelligence®, the company,s panomic, comprehensive tumor profiling ... several rare and difficult to treat gynecological cancers ... potential to improve patient outcomes. These studies were ... Society of Gynecologic Oncology (SGO) 2015 Annual Meeting ...
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... 27, 2015 Earlier this year, the ... of hair regrowth in adult men and women with ... Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification of ... by products that over-promise and under-deliver, FDA Clearance underscores ... and confidence among more than 80 million men and ...
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... Uterine fibroids affect more than 30% of American women. ... require fibroid treatment . Uterine fibroids treatment ... cause pressure on other organs (such as the bladder), grow ... fibroids symptoms usually cause heavy or abnormal bleeding and discomfort, ...
... Pepscan Therapeutics Announces Establishment of Scientific Advisory Board -- LELYSTAD, The Netherlands, September 28, 2010 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... to Push Scientific Search and Discovery to the... -- AMSTERDAM, September 28, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:Dr. Ramin Mirhashemi, MD of Gynecological Oncology Associates Discusses Uterine Fibroid Treatment with da Vinci Robotic Hysterectomy Surgery 2Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 2Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 3Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 4Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 5Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 6Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 7Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 2Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 3Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 4Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 5Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 6Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 7Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 8Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 9Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level 10
(Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... of the "Access Control Market by Product, Application ... 2020" report to their offering. , ... expected to reach $10.4 billion by 2020, with an ... market report covers the products types such as contact ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... The world,s smallest species of snake, with adults averaging just ... Caribbean island of Barbados. The species -- which is ... rest comfortably on a U.S. quarter --was discovered by Blair ... his colleagues also are the discoverers of the world,s smallest ...
... last decade, childhood obesity has grown into an epidemic, ... recommendations that pediatricians check toddlers for elevated cholesterol. ... intervene. A study presented at a pediatric research ... as early as age two, when children reach a ...
... history of science and technology, there is an ... developments converge that make it possible to recognize ... biomechanics and astrobiology with more recent developments of ... now well established in the lexicon of modern ...
Cached Biology News:World's smallest snake found in Barbados 2World's smallest snake found in Barbados 32 years old -- a childhood obesity tipping point? 2The emerging scientific discipline of aeroecology 2
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biotin d anti-mouse Tim-1...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Biology Products: